Tinostamustine for T-cell prolymphocytic leukemia treatment patent

This document is a USPTO patent application (US20260083707A1) filed by Purdue Pharma L.P. on July 28, 2025. It claims tinostamustine or a pharmaceutically acceptable salt thereof for use in treating T-cell prolymphocytic leukemia (T-PLL).

This is a patent application, not a regulatory rule or guidance. It does not impose new compliance obligations on entities outside of the patent application process itself. Companies involved in pharmaceutical development, particularly in oncology, should be aware of this patent filing as it pertains to intellectual property in the treatment of T-PLL.